Allegro, Senju team up to develop treatment of vascular eye diseases
Senju acquired the rights to co-develop and market Allegro's integrin peptide therapy for intravitreal injection for vascular eye diseases such as AMD and diabetic macular edema.
San Juan Capistrano, CA, and Osaka, Japan-Allegro Ophthalmics LLC and Senju Pharmaceutical Co. Ltd. have entered into a collaboration and license agreement to develop and market Allegro’s Integrin Peptide Therapy in Japan. The pairing aims to improve the quality of life for patients at risk of blindness due to vascular eye diseases by establishing Integrin Peptide Therapy as the first-in-class treatment.
Under the terms of the agreement, Senju will acquire the rights to co-develop and market Allegro’s Integrin Peptide Therapy in Japan as an intravitreal injection for vascular eye diseases such as wet age-related macular degeneration and diabetic macular edema. In exchange for these rights, Senju has agreed to pay Allegro an 8-digit upfront license fee, additional development and sales milestone fees, and a percentage royalty on net sales.
